Beginning Nov. 1, 2025, Novartis will launch a direct-to-patient (DTP) platform in the United States that offers cash-paying patients prescribed Cosentyx (secukinumab) the option to purchase it at a 55% discount off the list price. The price offered to cash-paying patients represents average savings that insurers and pharmacy benefit managers receive. Airsupra (albuterol/budesonide) has a list price of $489.25 for one inhaler and is an asthma rescue inhaler. The current list price of Sotyktu is $6,828 for a 30-day supply. This offer builds upon Bristol Myers Squibb’s existing offer of more than 40% off the Eliquis (apixaban) list price.